...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International clinical psychopharmacology >A score for predicting response to pharmacotherapy in obsessive-compulsive disorder.
【24h】

A score for predicting response to pharmacotherapy in obsessive-compulsive disorder.

机译：强迫症预测药物治疗反应的分数。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

SUMMARY: Although there have been many attempts to find predictors of therapeutic response to antidepressant treatment of obsessive-compulsive disorder (OCD), few reports have evaluated the joint predictive value of a number of clinical characteristics. This study aimed to identify clinical predictors of outcome in OCD, and to develop an easily applicable method to predict response to drug treatment. One hundred and fifty patients with primary OCD according to DSM-IV criteria were randomly assigned in a 12-week, double-blind, comparison trial with a selective serotonin reuptake inhibitor (paroxetine), and a serotonin-noradrenaline reuptake inhibitor (venlafaxine). The primary efficacy parameter was the Yale-Brown obsessive-compulsive scale (Y-BOCS) score, and response to treatment was prospectively defined as a >/= 35% decrease from the beginning. A stepwise multivariate analysis was used to identify predictors. The absence of previous therapies, moderate baseline severity of obsessive-compulsive symptoms (Y-BOCS score < 23), and low Hamilton Depressive Rating Scale scores (6-15) were found to be prognostic determinants of good response to pharmacotherapy. The prognostic ability of the prediction model to discriminate between responders and non-responders was quantified as the area under the receiver operating/operator characteristic curve (ROC area), which was 0.71 (95% confidence interval 0.63-0.8), demonstrating a reasonable discriminatory power. This study is the first to present a model that can estimate by the use of prediction rules the probability of treatment response to antidepressants in patients with OCD.
机译：简介：尽管已经进行了很多尝试来寻找强迫症（OCD）抗抑郁治疗的治疗反应预测因子，但很少有报道评估许多临床特征的联合预测价值。这项研究旨在确定OCD结局的临床预测指标，并开发一种易于应用的方法来预测对药物治疗的反应。根据DSM-IV标准，将150名患有原发性强迫症的患者随机分为一项为期12周的双盲比较试验，该试验采用选择性5-羟色胺再摄取抑制剂（帕罗西汀）和5-羟色胺-去甲肾上腺素再摄取抑制剂（文拉法辛）。主要疗效参数是耶鲁-布朗强迫症量表（Y-BOCS）评分，对治疗的反应前瞻性定义为从一开始降低> / = 35％。使用逐步多元分析来确定预测因素。没有先前的疗法，强迫症症状的基线严重程度中等（Y-BOCS得分<23）和汉密尔顿抑郁等级量表得分低（6-15）被认为是对药物治疗反应良好的预后决定因素。预测模型区分响应者和非响应者的预后能力被量化为接收者操作/操作者特征曲线下的面积（ROC面积），该面积为0.71（95％置信区间0.63-0.8），证明了合理的区别功率。这项研究是第一个提出可以通过使用预测规则来估计强迫症患者抗抑郁药治疗反应可能性的模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号